How I Manage Transplant Ineligible Patients with Myelodysplastic Neoplasms by Carmelo Gurnari, Zhuoer Xie, Amer M. Zeidan

Get full text

Clonal cytopenia of undetermined significance: definitions, risk and therapeutic targets by Cristian C. Taborda, Amer M. Zeidan, Lourdes M. Mendez

Get full text

Patients’ perspectives on oral decitabine/cedazuridine for the treatment of myelodysplastic syndromes/neoplasms by Amer M. Zeidan, Kate Perepezko, Tehseen Salimi, Terri Washington, Robert S. Epstein

Get full text

P741: PATIENTS’ PERSPECTIVES ON ORAL DECITABINE AND CEDAZURIDINE FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES by Amer M. Zeidan, Kate Perepezko, Tehseen Salimi, Terri Washington, Robert Epstein

Get full text

Hyflex CM and EDM from Shape Memory to Control Memory. by Jamal A. Abu Al‑Timan, Iman M. Al‑Zaka, Baidaa M. Zeidan

Get full text

Use of immunosuppressive therapy for management of myelodysplastic syndromes: a systematic review and meta-analysis by Maximilian Stahl, Jan Philipp Bewersdorf, Smith Giri, Rong Wang, Amer M. Zeidan

Get full text

PB2021: PHASE 2 STUDY OF ORAL DECITABINE/CEDAZURIDINE IN COMBINATION WITH MAGROLIMAB FOR PREVIOUSLY UNTREATED SUBJECTS WITH INTERMEDIATE TO VERY HIGH-RISK MYELODYSPLASTIC SYNDROMES... by Amer M. Zeidan, Karen Mosher, Sonia Souza, Beloo Mirakhur, Harold Keer, Jason Taylor

Get full text

Epigenetics in Cancer: A Hematological Perspective. by Maximilian Stahl, Nathan Kohrman, Steven D Gore, Tae Kon Kim, Amer M Zeidan, Thomas Prebet

Get full text

Spatial modeling of land resources and constraints to guide urban development in Saudi Arabia’s NEOM region using geomatics techniques by Haya M. Alogayell, Ahmed Kamal, Ibtesam I. Alkadi, Mona S. Ramadan, Rasha H. Ramadan, Ali M. Zeidan

Get full text

Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and... by Jan Philipp Bewersdorf, Smith Giri, Rong Wang, Robert T. Williams, Martin S. Tallman, Amer M. Zeidan, Maximilian Stahl

Get full text

P541: REAL-WORLD USE OF VENETOCLAX (VEN) IN PATIENTS (PTS) WITH ACUTE MYELOID LEUKEMIA (AML) IN A US REAL-WORLD EVIDENCE DATABASE (COTA) by Amer M. Zeidan, Leyla Hernandez- Donoso, Sejla Hodzic, Henry Owusu, Dhrubajyoti Pathak, Summera Zhou, Eytan Stein

Get full text

Using 6-CIT, P300 encephalography, and pro-inflammation assessments for screening age-related cognitive decline and exploring associated risk factors in Egyptian elderly by Mai S. Saleh, Asmaa F. Galal, Sara F. Sallam, Noha A. Mowaad, Hala M. Zeidan, Adel Hashish, Hala R. Elhabashy, Ola A. Heikal

Get full text

Case Report of a Patient with Left Ventricular Assistance Device Undergoing Chemotherapy for a New Diagnosis of Lung Cancer by Maliha Khan, Anum Wasim, Aibek E. Mirrakhimov, Blaithin A. McMahon, Daniel P. Judge, Linda C. Chu, Ashtami Banavali, Amer M. Zeidan

Get full text

PB1885: PHASE 1 STUDY OF ZIFTOMENIB IN COMBINATION WITH VENETOCLAX, VENETOCLAX/AZACITIDINE, OR STANDARD INDUCTION (7 + 3) CHEMOTHERAPY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA by Amer M Zeidan, Amir Fathi, Ghayas Issa, Harry Erba, Julie Ahsan Mackey, Daniel Corum, Blake Tomkinson, Tom Kozlek, Mollie Leoni, Eunice Wang

Get full text

P570: REAL-WORLD EFFICACY OUTCOMES OF VENETOCLAX PLUS AZACITIDINE VS INTENSIVE CHEMOTHERAPY FOR INDUCTION THERAPY IN ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA by A. M. Zeidan, D. A. Pollyea, U. Borate, A. Vasconcelos, R. Potluri, D. Rotter, Z. Kiendrebeogo, L. Gaugler, G. Bonifacio, T. Prebet, C. Chen

Get full text

A phase I/II multicenter, open-label, dose escalation and randomized trial of BI 836858 in patients with low- or intermediate-1-risk myelodysplastic syndrome by Rami S. Komrokji, Hetty E. Carraway, Ulrich Germing, Martin Wermke, Amer M. Zeidan, Eric Fu, Björn Rüter, Ute Burkard, Annika Osswald, James M. Foran

Get full text

PB2010: FIRST-LINE TREATMENT PATTERNS AND OUTCOMES AMONG PATIENTS WITH NEWLY DIAGNOSED MYELODYSPLASTIC SYNDROMES: A GLOBAL, RETROSPECTIVE OBSERVATIONAL COHORT STUDY by Amer M. Zeidan, Aleksandra Butrym, Aylin Yucel, Gaurav Deshpande, Min Che, Tao Gu, Hong Xiao, Dimana Miteva, Jose Alberto Nadal, T. Kim Le, Argiris Symeonidis

Get full text

P766: CLINICAL OUTCOMES IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES RECEIVING HYPOMETHYLATING AGENTS: A LARGE POPULATION-BASED ANALYSIS by A. M. Zeidan, E. S. Mearns, C. Ng, A. Shah, N. Lamarre, A. Yellow-Duke, N. Alrawashdh, B. Yang, W. Cheng, C. N. Bui, A. Svensson

Get full text

Treatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: a population-based analysis by Mengyang Di, Jessica B. Long, Shalin K. Kothari, Tarsheen Sethi, Amer M. Zeidan, Nikolai A. Podoltsev, Rory M. Shallis, Rong Wang, Xiaomei Ma, Scott F. Huntington

Get full text

Integrated genetic, epigenetic, and immune landscape of mutant AML and higher risk MDS treated with azacitidine by Amer M. Zeidan, Jan Philipp Bewersdorf, Vanessa Hasle, Rory M. Shallis, Ethan Thompson, Daniel Lopes de Menezes, Shelonidta Rose, Isaac Boss, Stephanie Halene, Torsten Haferlach, Brian A. Fox

Get full text